ReviewACS biomaterials science & engineering2020
Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.
Review in ACS biomaterials science & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review.Infection and drug resistance · 2025Review
- The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2.ACS omega · 2024Review
- Immunostimulatory DNA Hydrogel Enhances Protective Efficacy of Nanotoxoids against Bacterial Infection.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.ACS applied bio materials · 2023Review
- Evaluating polymeric biomaterials to improve next generation wound dressing design.Biomaterials research · 2022Review
- Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic.Biosafety and health · 2022Review
- The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.DNA and cell biology · 2022Review
- Titrating Polyarginine into Nanofibers Enhances Cyclic-Dinucleotide AdjuvanticityACS biomaterials science & engineering · 2021Article
- Design of Dissolvable Microneedles for Delivery of a Pfs47-Based Malaria Transmission-Blocking Vaccine.ACS biomaterials science & engineering · 2021Article
- Review
- Development of vaccine formulations: past, present, and future.Drug delivery and translational research · 2021Review
- Novel approaches for vaccine development.Cell · 2021Review
- Tabletized Supramolecular Assemblies for Sublingual Peptide Immunization.Advanced healthcare materials · 2021Article
- Biomaterials-based formulations and surfaces to combat viral infectious diseases.APL bioengineering · 2021Review
- Opportunities for biomaterials to address the challenges of COVID-19.Journal of biomedical materials research. Part A · 2020Review
- Highlights in Mesoporous Silica Nanoparticles as a Multifunctional Controlled Drug Delivery Nanoplatform for Infectious Diseases Treatment.Pharmaceutical research · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the success of vaccines in preventing many infectious diseases, effective vaccines against pathogens with ongoing challenges - such as HIV, malaria, and tuberculosis - remain unavailable. The emergence of new pathogen variants, the continued prevalence of existing pathogens, and the resurgence of yet other infectious agents motivate the need for new, interdisciplinary approaches to direct immune responses. Many current and candidate vaccines, for example, are poorly immunogenic, provide only transient protection, or create risks of regaining pathogenicity in certain immune-compromised conditions. Recent advances in biomaterials research are creating new potential to overcome these challenges through improved formulation, delivery, and control of immune signaling. At the same time, many of these materials systems - such as polymers, lipids, and self-assembly technologies - may achieve this goal while maintaining favorable safety profiles. This review highlights ways in which biomaterials can advance existing vaccines to safer, more efficacious technologies, and support new vaccines for pathogens that do not yet have vaccines. Biomaterials that have not yet been applied to vaccines for infectious disease are also discussed, and their potential in this area is highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.